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Does the cancer drugs fund lead to faster
uptake of cost-effective drugs? A time-trend
analysis comparing England and Wales
C Chamberlain*,1, S M Collin1, P Stephens2, J Donovan1, A Bahl3 and W Hollingworth1
1School of Social and Community Medicine, University of Bristol, 39 Whatley Road, Bristol BS8 2PS, UK; 2IMS Health,
210 Pentonville Road, London N1 9JY, UK and 3Bristol Haematology and Oncology Centre, University Hospitals Bristol,
Horfield Road, Bristol BS2 8ED, UK
Background: The Cancer Drugs Fund (CDF) provides d200 million annually in England for ‘anti-cancer’ drugs.
Methods: We used a controlled pre-/post-intervention design to compare IMS Health dispensing data for 15 cancer drugs
(2007–2012) in England vs Wales, stratified by pre-CDF NICE drug approval status (rejected, mixed recommendations,
recommended, not appraised).
Results: The CDF was associated with increased prescribing in England for three of five drugs rejected or with mixed NICE
recommendations. The prescribing volume ratios (PVR) ranged from 1.29 (95% CI 1.00, 1.67) for sorafenib to 3.28 (2.59, 4.14) for
bevacizumab (NICE rejected) and 0.93 (0.81, 1.06) and 1.35 (1.21, 1.49) for sunitinib and imatinib respectively (mixed
recommendations). Post CDF prescribing in England increased for both drugs awaiting NICE appraisal pre-CDF (lapatinib
PVR¼ 7.44 (5.81, 9.54), panitumumab PVR¼ 5.40 (1.20, 24.42)) and subsequently rejected. The CDF was not associated with
increased prescribing in England of NICE-recommended drugs. The three most recently launched, subsequently recommended
drugs were adopted faster in Wales (from pazopanib PVR¼ 0.51 (0.28, 0.96) to abiraterone PVR¼ 0.78 (0.61–0.99)).
Interpretation: These data indicate that the CDF is used to access drugs deemed not cost-effective by NICE. The CDF did not
expedite access to new cost-effective cancer agents prior to NICE approval.
Cancer is the leading cause of death in the UK. Cancer drugs
account for an increasing proportion of developed-country health
budgets (Sullivan et al, 2011). Restricted access to cancer drugs has
been cited as an important contributor to relatively poor survival
from cancer in UK (Wilking and Jonsson, 2005; Lichtenberg, 2009),
although this interpretation is controversial (Coleman, 2007).
In 2010, the UK health minister pledged to create a Cancer Drugs
Fund (CDF) ‘addressing the disparity in patients’ access to cancer
drugs in England compared with other countries’ (Department of
Health, 2010). The CDF was conceived ‘so that cancer sufferers and
their families could benefit from drugs that their doctors believe
could improve their quality of life’ (Department of Health, 2010).
Specifically, the Fund was to provide access to (a) drugs not yet
appraised by NICE, (b) NICE appraised drugs found to be not cost-
effective, or (c) drugs used in novel indications or formulations,
which had not been licensed.
The CDF was introduced in England in October 2010 (Richards,
2004). A d50 million interim CDF (October 2010 to March 2011,)
was superseded by a d200 million annual CDF. The CDF was
intended to be a funding ‘stop-gap’, pending the introduction of
value-based pricing in 2014. However, the Government has
announced a further d400 million investment to continue the CDF
beyond 2014 (Cancer Research UK, 2013). There is an imperative for
NHS funds to be spent efficiently (Department of Health, 2013) and
in the current financial climate (Ford, 2013), it is more important than
ever to evaluate how ring-fenced money for the CDF has been spent.
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Box 1. Technology appraisal decisions and cancer drugs 2007–12
Drug
Appraisal No.
Release date
Decision
Cancer type
Appraisal No.
Release date
Decision
Cancer type
Appraisal No.
Release date
Decision
Cancer type
Appraisal No.
Release date
Decision
Cancer type
Appraisal No.
Release date
Decision
Cancer type
Bevacizumab TA178* TA212* TA214 TA242* TA263*
08/09 12/10 02/11 01/12 08/12
NR NR NR NR NR
Renal cell Colorectal Breast Colorectal Breast
Sorafenib TA178* TA189
08/09 05/10
NR NR
Renal cell Hepatocellular
Imatinib** TA196 TA209 TA241 TA251
08/10 11/10 01/12 04/12
NR NR NR R
GI stromal GI stromal CML CML
Cetuximab TA145 TA172 TA176 TA242*
06/08 06/09 08/09 01/12
R NR R NR
Head and neck Head and neck Colorectal Colorectal
Sunitinib TA169 TA178* TA179
03/09 08/09 09/09
R NR R
Renal Cell Renal cell GI stromal
Rituximab TA137* TA174 TA193 TA226 TA243*
02/08 07/09 07/10 06/11 01/12
R R R R R
Follicular L CLL CLL Follicular L Follicular L
Capecitabine TA191 TA212* TA263*
07/10 12/10 08/12
R NR NR
Gastric Colorectal Breast
Lenalidomide TA171
06/09
R
MM
Pegylated TA222
Liposomal 04/11
Doxorubicin NR
Hydrochlorideþ Ovarian
Bortezomib TA129 TA228
10/07 07/11
R R
Ovarian MM
Lapatinib TA257
06/12
NR
Breast
Panitumumab TA242*
01/12
NR
Colorectal
Abiraterone TA259
06/12
R
Prostate
Bendamustine TA216
02/11
R
CLL
Pazopanib TA215
02/11
R
Renal cell
Abbreviations: CLL¼ chronic lymphocytic leukaemia; CML¼ chronic myeloid leukaemia; follicular L¼ follicular lymphoma; GI¼gastrointestinal; MM¼multiple myeloma; Technology
appraisals (TA) that occurred before August 2007 or after December 2012, or were terminated or withdrawn are not included in this table. NR: not NICE recommended, shaded cells. R: NICE
recommended, not shaded *signifies technology appraisals affecting multiple drugs within the table. **Imatinib is classed as ‘mixed’ due to NICE decisions prior to the study period (R 09/02,
R 10/03, R 10/04) þPegylated liposomal doxorubicin hydrochloride (PLDH) was recommended by NICE prior to the study period (R 05/05).
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Our aim was to explore the impact of the CDF on access to
cancer drugs in England, compared with Wales, using secondary-
care data relating to the dispensing of 15 high-cost cancer drugs
from 2007 to 2012. Specifically, we aimed to test several
hypotheses: (a) that drugs which were deemed not cost-effective
in some or all indications by NICE would be prescribed more in
England than in Wales following the CDF; (b) that prescribing of
drugs that NICE recommended before the CDF would not increase
faster in England compared with Wales post CDF and (c) that
drugs that had no NICE appraisal pre-CDF or were launched
around the time of the CDF would demonstrate greater prescribing
volumes in England compared with Wales.
MATERIALS AND METHODS
IMS Health secondary-care data for high-cost cancer drugs were
compared between England and Wales from August 2007 to
December 2012. IMS Health is an established data source used
extensively by pharmaceutical companies, government agencies,
policy-makers and researchers (Richards, 2004, 2010; The
Information Centre for Health and Social Care, 2012). IMS Health
data in this analysis were obtained exclusively from hospital
pharmacies. Hospitals provide monthly extracts on a routine basis
to IMS relating to the volume of all drugs dispensed, or recorded as
being dispensed, by that pharmacy. We excluded private prescrip-
tion data from our analysis to focus on NHS prescribing.
We reviewed NICE technology appraisal (TA) decisions
between 1 March 2000 and 23 January 2012 to identify appraisals
of pharmaceuticals for the treatment of cancer. We selected drugs
that were prescribed on the CDF in 10 or more cases in each of
four regions that published annual reports (NHS London,
Yorkshire and Humber, West Midlands and North West) during
the period April 2011 to March 2012. We excluded drugs that did
not have anti-tumour activity (NHS England, 2013a) and drugs
used predominantly in pediatric oncology. This resulted in a list of
24 drugs. We stratified these drugs by tumour type and NICE
decision (recommended/not recommended/not appraised). For
strata that contained more than one drug, we randomly selected
one drug for inclusion. This resulted in a list of 18 drugs. Two
further drugs were excluded due to missing or zero prescribing
data for more than 25% of the available months since launch
(cabazitaxel and ipilimumab) and one additional drug (Paclitaxel)
was excluded because it had no NICE appraisal since 2007. The
final list of 15 drugs, with NICE TA decisions and cancer
indication(s) are included in Box 1.
We classified the drugs into five groups according to their pre-
CDF NICE appraisal status (Table 1). Group 1 included drugs that
had been rejected for all indications. Group 2 included drugs that
had mixed recommended and rejected decisions (for different
indications). Group 3 included drugs that were recommended for
all indications. Group 4 contained all drugs that had no NICE
appraisal decision prior to the CDF. Group 5 included new drugs
launched within 3 months or after the introduction of the CDF.
A priori hypotheses were developed for the influence of the
CDF for each of the five group classifications (Table 1). We
hypothesised that post CDF prescribing of drugs rejected by NICE
for all or some indications (Groups 1 and 2) would increase in
England relative to Wales, representing prescribing for indications
considered by NICE to be not cost-effective. We hypothesised
that there would be no change in post CDF prescribing of
drugs approved by NICE for all indications pre-CDF (Group 3) in
England relative to Wales. We also hypothesised that relative
prescribing of drugs with no NICE appraisal or launch dates
around the introduction of the CDF (Groups 4 and 5) would be
higher in England relative to Wales due to faster uptake of drugs
awaiting appraisal. For groups 1–4 we conducted a controlled
before-and-after study comparing prescribing volumes in England
and Wales before and after the CDF. For group 5, we compared
prescribing volumes in England and Wales post CDF.
Prescribing volumes (milligrams per 1000 population) were
plotted using 3 monthly moving averages per head of population
(mid-year ONS population estimates) for England and Wales. For
each drug, negative binomial regression was used to analyse
prescribed volume per head of population. Negative binomial
regression was chosen because some count data were overdispersed
(Kim and Kriebel, 2009). For drugs in groups 1–4, the number of
milligrams prescribed per month between October 2009 and
December 2012, offset by population size, was regressed on the
independent variables of country (Wales¼ 0, England¼ 1), period
(pre-CDF¼ 0, post CDF¼ 1) and an interaction term between
country and period (i.e., the prescribing volume ratio (PVR)).
Table 1. A priori hypothesis table of cancer drug classification
Drug groups Hypothesis Explanation Drugs
Group 1: Rejected by NICE for all
indication(s) considered pre-CDF
Relative to pre-CDF prescribing levels,
prescribing will increase faster in England
compared with Wales following the CDF
Increased prescribing in England since drugs that were
previously declined on cost-effectiveness grounds can
now be prescribed
Bevacizumab
Sorafenib
Group 2: Mixed recommended
and rejection decisions by NICE
for differing indications pre-CDF
Relative to pre-CDF prescribing levels,
prescribing will increase faster in England
compared with Wales following the CDF
Increased prescribing in England for indications where the
drug was previously declined on cost-effectiveness
grounds
Imatinib
Cetuximab
Sunitinib
Group 3: Recommended by NICE
for all indications considered
pre-CDF
Relative to pre-CDF prescribing levels,
prescribing will not increase faster in England
compared with Wales following the CDF
No difference between English and Welsh prescribing for
recommended drugs since these drugs could already be
accessed through NHS funding pre-CDF
Rituximab
Capecitabine
Lenalidomide
PLDH
Bortezomib
Group 4: No NICE appraisal
decision pre- CDF
Relative to pre-CDF prescribing levels,
prescribing will increase faster in England
compared with Wales following the CDF
Drugs without NICE decisions can now be accessed via
the CDF leading to increased prescribing in England, but
not in Wales
Lapatinib
Panitumumab
Group 5. Drugs launched
immediately prior to or after the
CDF
Prescribing for these drugs will increase
faster in England compared with Wales
New drugs may be more rapidly adopted in England
following the introduction of the Cancer Drugs Fund,
compared with Wales where prescribing increases may be
delayed pending NICE recommendation.
Abiraterone
Bendamustine
Pazopanib
Abbreviations: CDF¼Cancer Drugs Fund; NHS¼ National Health Service; NICE¼National Institute for Health and Care Excellence; PLDH¼pegylated liposomal doxorubicin hydrochloride.
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A PVR coefficient 41 indicates an increase in post-CDF
prescribing in England relative to Wales. For drugs in group 5,
the number of milligrams prescribed per month between October
2010 and December 2012, offset by population size, was regressed
on the independent variable of country (Wales¼ 0, England¼ 1).
A country coefficient 41 indicates faster uptake of prescribing in
England than Wales. All analyses were conducted using Stata
(version 12.0, StataCorp LP, College Station, TX, USA).
Ethical approval for the use of IMS Health cancer drug
dispensing data was granted by the South West Research Ethics
Committee.
RESULTS
Group 1 (drugs rejected by NICE pre-CDF). In the year before
the CDF, prescribing volumes in England and Wales were similar
for bevacizumab but widely different for sorafenib, where rates
were much higher in Wales (Figure 1A and B). Post CDF,
bevacizumab prescribing increased more than two-fold in England
compared with a 63.8% increase in Wales, despite four further
NICE ‘not recommended’ decisions. The mean prescribing volume
of sorafenib in England over the post-CDF period was 25.4%
higher than in the 1 year pre-CDF period, compared with only a
2.5% rise in Wales. Regression analyses (Table 2) showed
correspondingly strong evidence of a large association between
the introduction of the CDF and increased prescribing in England
compared with Wales for bevacizumab (PVR¼ 3.28 (95% CI
2.59–4.14), Po0.001), but only marginal evidence of a modest
association for sorafenib (PVR¼ 1.29 (95% CI 1.00–1.67),
P¼ 0.05).
Group 2 (mixed NICE recommended and rejection decisions
pre-CDF). In the year pre-CDF, prescription rates of imatinib
were substantially higher in England compared with Wales
(Figure 2A). Immediately prior to the CDF, following the first
NICE rejection, imatinib prescribing in Wales declined, whereas
imatinib prescribing in England declined more slowly despite two
further post-CDF NICE rejections. Regression analysis demon-
strated strong evidence of a modest association between the
introduction of the CDF and increased prescribing in England
compared with Wales (PVR¼ 1.35 (95% CI 1.21–1.49), Po0.001)
(Table 2). Cetuximab prescribing in the year pre-CDF was slightly
higher in Wales than in England (Figure 2B). The post CDF
prescription rate rose faster in England, and was higher than Wales
from January 2012 onwards. There was strong evidence of a
modest association between the CDF and increased prescribing in
England compared with Wales (PVR 1.29 (1.04 to 1.60), P¼ 0.02)
(Table 2). Prescribing volumes of sunitinib declined in England
and Wales (18.3% England, 9.6% Wales) following the introduc-
tion of the CDF. Sunitinib had received two NICE recommenda-
tions and one rejection in 2009, pre-CDF (Box 1). There was no
good evidence of an association between the CDF and prescribing
of sunitinib in England, compared with Wales (PVR¼ 0.93 (95%
CI 0.81–1.06), P¼ 0.27) (Table 2).
Group 3 (NICE recommended for all indication(s) pre-CDF).
There was no evidence the CDF influenced prescribing of
NICE recommended drugs in England, compared with Wales
(all PVR confidence intervals include 1.00, all P40.2) (Table 2,
Figure 3A–E). For most of these drugs, prescribing increased in
England and Wales following NICE ‘recommended’ verdicts. A
sharp decline in pegylated liposomal doxorubicin hydrochloride
prescribing occurred in England and Wales in the period after the
NICE rejection (April 2011) (Figure 3D).
Group 4 (drugs awaiting NICE appraisal pre-CDF). Following
the CDF, English and Welsh prescribing volumes diverged
dramatically: compared with the year pre-CDF, lapatinib prescrip-
tion volume increased nearly three-fold (2.72) in England while
prescription volumes declined by 32.1% in Wales. Panitumumab
prescribing increased by 73.1% in England compared with a 48.7%
drop in Wales (Figure 4A and B). Regression analysis (Table 2)
showed strong evidence of a large association between the CDF
and increased prescribing in England compared with Wales for
both drugs (lapatinib PVR 7.44 (95% CI 5.81–9.54), Po0.001,
panitumumab PVR 5.40 (95% CI 1.20–24.42), P¼ 0.03). NICE
subsequently rejected both lapatinib and panitumumab on the
grounds of cost-effectiveness (Box 1).
Group 5 (more recent drugs). All three recently released drugs
(abiraterone, bendamustine and pazopanib) had lower prescribing
volumes in England than in Wales: abiraterone, 22% lower in
England, PVR¼ 0.78 (95% CI 0.61–0.99), P¼ 0.04; bendamustine,
25% lower in England, PVR¼ 0.75 (95% CI 0.64–0.88), P¼ 0.002,
and pazopanib, 49% lower in England, PVR¼ 0.51 (95% CI 0.28–
0.96), P¼ 0.04. All three drugs were recommended by NICE
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Figure 1. Solid trend line (blue): England 3 monthly moving average.
Dashed trend line (red): Wales 3 monthly moving average. Thick
line-Cancer Drugs Fund established (October 2010). Solid line-NICE
recommended decision. Dashed line-NICE not recommended
decision. Rejected by NICE for all indications (sorafenib, bevacizumab).
(A) Bevacixumab. (B) Sorafenib. The color reproduction of this
figure is available on the BJC journal online.
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following the introduction of the CDF (2011/12) (Table 3,
Figure 5A–C).
DISCUSSION
The CDF was strongly associated with higher prescription volumes
in England compared with Wales for the majority of drugs, which
NICE had rejected for some or all indications pre-CDF and for
drugs, which NICE had not appraised pre-CDF, but subsequently
rejected. Drugs that were recommended by NICE prior to the CDF
showed no evidence of an effect of the CDF on prescribing in
England compared with Wales. Contrary to our hypothesis, Wales
had faster adoption of the most recent drugs launched in 2010/11
and subsequently recommended by NICE. These results suggest
that drugs deemed not cost-effective by NICE are accessed more in
England than in Wales. There is no evidence that the CDF results
in faster uptake of drugs later demonstrated to be cost-effective.
We have used an established data source to quantify high-cost
cancer drug prescribing volumes over a period of radical change in
access to cancer drugs. The implementation of the CDF in England
but not in Wales provided a natural before-and-after controlled
‘experiment’. We randomly selected drugs, stratified by NICE
recommendation, in order to explore the interplay between the
CDF and NICE guidance. The use of longitudinal data allows trend
analysis, rather than using a more limited ‘snapshot’ in time which
may obscure the complexities of evolving NICE recommendations.
We chose not to adjust for age-standardised incidence of cancer
in England and Wales in our model. Appropriate adjustment for
eligibility for the cancer drugs evaluated in our study would require
data on staging and comorbidities. This level of detail is not
routinely available. Differences in clinical need for chemotherapy
might account for some differences in prescribing volumes
between England and Wales, but cannot account for the dramatic
divergence in post-CDF prescribing of drugs such as bevacizumab
or lapatinib.
There are important potential limitations with IMS Health data.
Hospitals were unable to supply data for around 3% of months to
IMS Health and those drugs prescribed in the community, via
homecare, privately, or as part of clinical trials have not been fully
captured.
Table 2. Mean prescribing volumes in England and Wales 12 months before and after the introduction of the CDF and PVR estimating the effect
of the CDF
Drug Country
Mean over 12-month pre-CDF
period (10/2009 to 10/2010)
(mg per 1000 pop)
Mean over post CDF period
(11/2010 to 12/2012)
(mg per 1000 pop) PVR (95% CI)a P-Value
Group 1: Rejected by NICE for all indications pre-CDF
Bevacizumab E 4.24 13.35 3.28 (2.59–4.14) o0.001
W 4.56 7.47 1.0
Sorafenib E 43.45 54.49 1.29 (1.00–1.67) 0.050
W 214.07 219.35 1.0
Group 2: Mixed recommended and rejected decisions by NICE pre-CDF
Imatinib E 643.16 616.82 1.35 (1.21–1.49) o0.001
W 348.00 236.76 1.0
Cetuximab E 8.21 14.65 1.29 (1.04–1.60) 0.020
W 9.24 14.82 1.0
Sunitinib E 18.70 15.27 0.93 (0.81–1.06) 0.266
W 27.64 25.00 1.0
Group 3: Recommended for all indications by NICE pre-CDF
Rituximab E 79.98 97.09 1.02 (0.93–1.13) 0.655
W 85.54 98.66 1.0
Capecitabine E 7955.36 5922.87 0.97 (0.91–1.04) 0.422
W 8784.06 8698.37 1.0
Lenalidomide E 6.31 9.53 1.11 (0.94–1.31) 0.226
W 5.50 7.03 1.0
PLDHb E 0.75 0.51 1.05 (0.48–2.31) 0.897
W 0.81 0.42 1.0
Bortezomib E 0.15 0.20 1.06 (0.89–1.27) 0.509
W 0.13 0.16 1.0
Group 4: No NICE appraisal decision
Lapatinib E 5.35 19.90 7.44 (5.81–9.54) o0.001
W 12.39 8.41 1.0
Panitumumab E 0.26 0.45 5.40 (1.20–24.42) 0.028
W 0.76 0.39 1.0
Abbreviations: CDF¼Cancer Drugs Fund; CI¼ confidence interval; E¼England; NICE¼National Institute for Health and Care Excellence; PVR¼prescribing volume ratios; W¼Wales.
aThe PVR for the effect of the CDF was estimated using a term for interaction between country and pre-/post-CDF period in a negative binomial regression model. The PVR is the additional
effect of the CDF on prescribing trends in England compared with Wales.
bPLDH Pegylated liposomal doxorubicin hydrochloride.
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IMS Health data cannot be disaggregated by indication; hence,
trends in drugs prescribed for multiple conditions (e.g. rituximab)
or multiple cancer types (e.g. bevacizumab) are challenging to
interpret. Furthermore, drugs that are currently ‘approved in all
indications’ might be prescribed for an indication that has not yet
been NICE appraised and might not be recommended by NICE in
the future. Similarly, historical NICE approval status is not always
a good indicator of the current cost-effectiveness of a drug. Also,
we cannot adjust for cross-border flows of patients, particularly for
rarer cancers with more centralised care, because IMS Health data
is collated by hospital rather than by patient residence. However, as
Welsh residents cannot access the CDF even when treated in an
English hospital, this is unlikely to account for the post-CDF
divergence observed, not withstanding the possibility that some
patients relocate residence to England after diagnosis (Borland,
2013). Finally, CDF funding may have knock-on effects on the
treatment pathway. Drugs funded by the CDF may supplant those
approved by NICE, or move these to a different line of therapy.
There is perhaps such an interaction between sunitinib, sorafenib,
everolimus, pazopanib and axitinib in renal cell carcinoma, which
may explain some of the differences between England and Wales.
Regional geographical variation in cancer prescribing is not
unique to UK and there is a growing literature on international
variability in access to cancer drugs (Jonsson and Wilking, 2007;
Verma et al, 2007; Kos et al, 2008; Richards, 2010; Ragupathy et al,
2012). In 2010, a UK report comparing international variability in
the use of cancer and non-cancer pharmaceuticals found that
‘countries that spend the most on health do not always have the
highest levels of (drug) usage and low spenders can be high users of
drugs’ (Richards, 2010). A number of social and geographical
factors have been shown to influence access to appropriate cancer
chemotherapy (Patel et al, 2007; Faden et al, 2009; Crawford et al,
2012). In 2004, ‘constraints in service capacity and differences in
clinical practice’ were highlighted as the main cause of variation in
UK prescribing of cancer drugs (Richards, 2004). Geographical
variation in clinical practice is not unique to cancer and has been
shown to be multifactorial (Appleby et al, 2011). There have been
limited peer-reviewed publications on cancer drug prescribing in
the UK since the introduction of the CDF. One empirical analysis
of prescribing in England considered time-trends in five commonly
prescribed CDF drugs. The results demonstrated a post-CDF
increase in prescribing for all five drugs. However, the increase was
less than anticipated suggesting that in actual practice, drugs were
used for shorter periods or at lower doses than in the clinical trials
(Stephens and Thomson, 2012).
Widely cited reports from the grey literature (Rarer Cancers
Foundation, 2011b, c) suggest that ‘people in Wales are now more
than five times less likely to gain access to a cancer drug that is not
routinely available than people in England’. However these results
were based on Freedom of Information requests covering different
periods for Wales (October 2009 to December 2010) and England
(October 2010 to March 2011) (Rarer Cancers Foundation, 2011c).
Response to FOI requests tends to be variable (Rarer Cancers
Foundation, 2011a) and their accuracy is unknown. The report was
restricted to drugs prescribed through the CDF in England and
drugs prescribed via ’Individual funding panels’ in Wales. There-
fore, it did not capture drugs prescribed via other routes (e.g.
clinical trials or off-label settings). The IMS Health data are
collected by hospital pharmacies and are not as restricted. This
may account for the higher volume of prescribing for some drugs
(e.g. sunitinib) observed in our study.
The intention of the CDF was to provide greater access to
cancer drugs, including those judged by NICE to be not cost-
effective and previously only available in ‘exceptional’ cases.
The CDF also intended to increase clinician involvement in cancer
drug decision panels (Stanton, 2010) and reduce delay in access to
drugs resulting from time taken in NICE appraisal. Critics of the
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Figure 2. Solid trend line (blue): England 3 monthly moving average.
Dashed trend line (red): Wales 3 monthly moving average. Thick
line-Cancer Drugs Fund established (October 2010). Solid line-NICE
recommended decision. Dashed line-NICE not recommended
decision. Mixed recommended and rejected decisions by NICE
pre-CDF (imatinib, cetuximab, sunitinib). (A) Imatinib. (B) Cetuximab.
(C) Sunitinib. The color reproduction of this figure is available
on the BJC journal online.
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Figure 3. Solid trend line (blue): England 3 monthly moving average. Dashed trend line (red): Wales 3 monthly moving average. Thick line-Cancer
Drugs Fund established (October 2010). Solid line-NICE recommended decision. Dashed line-NICE not recommended decision. Recommended
by NICE for all indications pre-CDF (rituximab, capecitabine, lenalidomide, doxorubicin, bortezomib). (A) Rituximab. (B) Capecitabine.
(C) Lenalidomide. (D) Pegylated liposomal doxorubicin hydrochloride (PLDH). (E) Bortezomib. The color reproduction of this figure is available
on the BJC journal online.
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Figure 4. Solid trend line (blue): England 3 monthly moving average.
Dashed trend line (red): Wales 3 monthly moving average. Thick line-
Cancer Drugs Fund established (October 2010). Solid line-NICE
recommended decision. Dashed line-NICE not recommended
decision. No NICE appraisal pre-CDF (lapatinib, panitumumab).
(A) Lapatinib. (B) Panitumumab. The color reproduction of this
figure is available on the BJC journal online.
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Figure 5. Solid trend line (blue): England 3 monthly moving average.
Dashed trend line (red): Wales 3 monthly moving average. Thick
line-Cancer Drugs Fund established (October 2010). Solid line-NICE
recommended decision. Dashed line-NICE not recommended
decision. Recently launched (o3months) pre-CDF or launched after
the CDF (abiraterone, bendamustine, pazopanib). (A) Abiraterone.
(B) Bendamustine. (C) Pazopanib. The color reproduction of this
figure is available on the BJC journal online.
Table 3. Prescribing volume ratios of recently launched drugs
Group 5:
Recently
launched
drugs Country
Mean over period
(since CDF or
drug launcha)
mg per 1000 pop
Prescribing
volume ratio
(95% CI)
E vs Wb P-value
Abiraterone E 463.69 0.78 (0.61–0.99) 0.043
W 619.69 1.0
Bendamustine E 1.12 0.75 (0.64–0.88) 0.002
W 1.35 1.0
Pazopanib E 62.32 0.51 (0.28–0.96) 0.036
W 123.68 1.0
Abbreviations: CDF¼Cancer Drugs Fund; CI¼ confidence interval; E¼England; W¼Wales.
aWhere the launch of the drug occurred after the introduction of the CDF, means are from drug
launch: for example, Abiraterone September 2011.
bThese regression analyses are based on the period from the start of the CDF or drug launch
(whichever came first) to the end of the study period. The prescribed volume ratio represents the
rate of prescribing in England compared with Wales during this period.
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CDF argue that the use of public money to access drugs that are
not cost-effective would introduce new inequity into NHS care
because of the opportunity cost for other patients if the NHS
spends money inefficiently (Howell, 2011; Thornton, 2011). Using
the CDF to routinely finance treatments that are outside their
licensed indication (‘off-label’) and outside the NHS exceptionality
processes or trial settings, may result in ethical concerns. For
instance, there could be provision of less-evidence based or
unlicensed care to patients, where alternative, more cost-effective
treatment exists. Evidence that investment in pharmaceuticals is
the most effective method to improve cancer survival in the UK is
highly contentious, and focusing on other aspects of diagnosis and
care may improve survival more significantly (Foot and Harrison,
2011). The reason for favouring cancer over other leading causes of
mortality and morbidity, such as heart disease, is also controversial
with preliminary research indicating the public do not support
the assertion that cancer is of greater importance (Linley and
Hughes, 2013).
Our finding of higher than anticipated prescribing of the three
newer drugs in Wales has several potential explanations. As Wales
is a relatively small country, prescribing volumes may simply
reflect the practice patterns of a small number of prescribers who
participate in trials or prescribers who are otherwise early adopters
of the new drugs. However, the CDF may also have an indirect
role. For example, uptake of abiraterone may be faster in Wales, as
there is more restricted access to alternative prostate cancer drugs
(e.g. Cabazitaxel), which have been rejected by NICE. Similarly
greater pazopanib use in Wales may also reflect preferential use
over drugs (e.g. bevacizumab) judged not cost-effective by NICE
for renal cell carcinoma. If this finding is replicated for other new
drugs, it may be indicative that by encouraging use of drugs
deemed not cost-effective by NICE, the CDF may be impacting on
early adoption of subsequent drugs that are more cost-effective.
We have demonstrated that access to cancer drugs in England
has improved for some patients since the launch of the CDF.
However, the persistent increase in prescribing of drugs, which are
deemed not cost-effective by NICE has important implications for
NHS resource allocation in England. The ramifications of the CDF
for Scotland and Wales, where patients cannot easily access these
cancer drugs, but who may experience a ‘creep’ in prescribing as a
result of decisions on their borders, also raises ethical, moral,
financial and policy concerns. In the short term, research into the
effect of the CDF on English regional variation in cancer drug
prescribing, and into the effect of the new National Cohort List
(NHS England, 2013b) (April 2013) is needed. In the long-term,
further research into public preferences for therapy for cancer vs
other diseases and mechanisms, such as value-based pricing
(Hughes, 2011), for making effective therapies available to the
NHS for an appropriate price are needed.
The CDF was associated with increased prescribing in England
compared with Wales of drugs deemed by NICE to be not cost-
effective for some or all indications. We observed faster uptake in
Wales of three recently launched cancer drugs subsequently
recommended by NICE, indicating that the CDF does not
necessarily speed up access to new cost-effective drugs, as
previously speculated.
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